Literature DB >> 28921267

Studies of the mechanism of nephrotoxicity of compound A in rats.

J L Martin1, L Kandel2, M J Laster2, R L Kerschmann3, E I Eger2.   

Abstract

CO2 absorbents acting on sevoflurane produce compound A [CF2=C(CF3)OCH2F]. Rats breathing 25-50 ppm of compound A for 3-12 h demonstrate corticomedullary renal injury. Several halogenated alkenes also produce a well described corticomedullary lesion by conversion of glutathione conjugates of these alkenes to cysteine s-conjugates and subsequent metabolism by renal cysteine conjugate β-lyase to nephrotoxic halothionoacetyl halides. We tested whether a similar mechanism explained the nephrotoxicity of compound A or whether an oxidative metabolism of compound A by cytochrome P-450 was required for the induction of nephrotoxicity. A closed rebreathing system was used and male Wistar rats were exposed for 1 h to: (1) oxygen alone; (2) 800 ppm compound A; (3) 800 ppm compound A after pretreatment with intraperitoneal aminooxyacetic acid (AOAA), 0.5 mmoles/kg, an inhibitor of renal cysteine conjugate β-lyase; (4) 600 ppm compound A; (5) 600 ppm compound A after pretreatment with intraperitoneal AOAA, 0.50 mmoles/kg plus acivicin (AT-125), 0.25 mmoles/kg, an inhibitor of gamma glutamyl transpeptidase; (6) 600 ppm compound A after pretreatment with 1600 mg/kg piperonyl butoxide (PB) subcutaneously, and (7) 600 ppm compound A after pretreatment with 100 mg/kg 1-aminobenzotriazole (ABT) by intraperitoneal injection (both PB and ABT inhibit cytochrome P-450s). All rats were killed 24 h following exposure to compound A or oxygen, or to pretreatments without compound A, and the kidneys were collected for histological analysis. Pretreatments given without compound A did not cause renal injury. Necrosis was found in 20.9±16.7% (mean±SD) of corticomedullary tubule cells following exposure of Wistar rats to 600 ppm compound A. Pretreatment with AOAA plus AT-125 increased necrosis to 57.9±32.6%, (P<0.005). PB or ABT given prior to compound A increased corticomedullary injury to 39.0±31.4% (P<0.02) and 51.2±31.8% (P<0.025), respectively. In rats exposed to 800 ppm compound A, pretreatment with AOAA increased necrosis from 63.8±30.1% to 81.2±27.7% (P<0.1). Unlike many other halogenated alkenes, compound A does not appear to produce renal injury by conversion of a cysteine S-conjugate to a toxic thiol, nor does injury require metabolism mediaited by cytochrome P-450. Injury may result from direct toxicity of compound A or by an undetermined metabolic pathway.

Entities:  

Keywords:  Anesthetics; Compound A; Sevoflurane; Toxicity; Volatile

Year:  1997        PMID: 28921267     DOI: 10.1007/BF02480002

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  31 in total

1.  Nephrotoxic amino acid and glutathione S-conjugates: formation and renal activation.

Authors:  M W Anders; L H Lash; A A Elfarra
Journal:  Adv Exp Med Biol       Date:  1986       Impact factor: 2.622

2.  Urinary metabolites of halothane in man.

Authors:  E N Cohen; J R Trudell; H N Edmunds; E Watson
Journal:  Anesthesiology       Date:  1975-10       Impact factor: 7.892

3.  Serum inorganic fluoride levels in mildly obese patients during and after sevoflurane anesthesia.

Authors:  H Higuchi; T Satoh; S Arimura; M Kanno; R Endoh
Journal:  Anesth Analg       Date:  1993-11       Impact factor: 5.108

4.  Serum and urinary inorganic fluoride concentrations after prolonged inhalation of sevoflurane in humans.

Authors:  Y Kobayashi; R Ochiai; J Takeda; H Sekiguchi; K Fukushima
Journal:  Anesth Analg       Date:  1992-05       Impact factor: 5.108

Review 5.  Glutathione conjugate mediated toxicities.

Authors:  T J Monks; M W Anders; W Dekant; J L Stevens; S S Lau; P J van Bladeren
Journal:  Toxicol Appl Pharmacol       Date:  1990-10       Impact factor: 4.219

6.  Purification and characterization of human kidney cytosolic cysteine conjugate beta-lyase activity.

Authors:  L H Lash; R M Nelson; R A Van Dyke; M W Anders
Journal:  Drug Metab Dispos       Date:  1990 Jan-Feb       Impact factor: 3.922

7.  Mechanism of S-(1,2-dichlorovinyl)glutathione-induced nephrotoxicity.

Authors:  A A Elfarra; I Jakobson; M W Anders
Journal:  Biochem Pharmacol       Date:  1986-01-15       Impact factor: 5.858

8.  The role of ortho-bromophenol in the nephrotoxicity of bromobenzene in rats.

Authors:  S S Lau; T J Monks; K E Greene; J R Gillette
Journal:  Toxicol Appl Pharmacol       Date:  1984-03-15       Impact factor: 4.219

9.  Detection of cysteine conjugate metabolite adduct formation with specific mitochondrial proteins using antibodies raised against halothane metabolite adducts.

Authors:  P J Hayden; T Ichimura; D J McCann; L R Pohl; J L Stevens
Journal:  J Biol Chem       Date:  1991-10-05       Impact factor: 5.157

10.  Toxicology of the fluoroalkenes: review and research needs.

Authors:  J W Clayton
Journal:  Environ Health Perspect       Date:  1977-12       Impact factor: 9.031

View more
  2 in total

1.  RE: Yuge O: Renal toxicity of compound A with sevoflurane anesthesia: the benefits of sevoflurane appear to outweight the risks (editorial).J. Anesth 11:1-2.

Authors:  Edmond I Eger; Jackie L Martin
Journal:  J Anesth       Date:  1997-12       Impact factor: 2.078

2.  Renal toxicity of compound A with sevoflurane anesthesia: The benefits of sevoflurane appear to outweigh the risks.

Authors:  Osafumi Yuge
Journal:  J Anesth       Date:  1997-03       Impact factor: 2.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.